Everything below concerns pentadecapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
| Property | Value | Notes |
|---|---|---|
| Amino acid count | 15 residues | Synthetic pentadecapeptide chain |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Molecular formula | C62H98N16O22 | Free peptide, without counter-ion |
| Theoretical mass | Approximately 1419.5 daltons | Varies slightly with adducts and counter-ions |
| Origin | Fragment of a human gastric juice protein | Source of the BPC designation |
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
== Chemical reactions == Due to its resonance stabilization, the peptide bond is relatively unreactive under physiological conditions, even less than similar compounds such as esters. Nevertheless, peptide bonds can undergo chemical reactions, usually through an attack of an electronegative atom on the carbonyl carbon, breaking the carbonyl double bond and forming a tetrahedral intermediate. This is the pathway followed in proteolysis and, more generally, in N–O acyl exchange reactions such as those of inteins. When the functional group attacking the peptide bond is a thiol, hydroxyl or amine, the resulting molecule may be called a cyclol or, more specifically, a thiacyclol, an oxacyclol or an azacyclol, respectively.
=== Disease diagnosis and monitoring === Disease diagnosis and monitoring of therapeutic efficacy is possible by detecting several biomarkers in body fluid. However, current tissue fluid extraction methods are pain-inducing, and it may take up to hours or days for samples to be analyzed in medical laboratories. MNs could collect body fluid in an almost painless manner, and it could provide immediate diagnosis when combined with a sensor. MNs allow penetration through the epidermis but not long enough to compress nerves in deeper layers, and thus, they are minimally invasive and almost painless. MNs' precision also allow the extraction of fluid surrounding diseased tissues, which may contain higher concentration of different biomarkers and specific biomarkers that are not present in the systemic circulation. These fluids provide more clinically significant and accurate values than those extracted from the systemic circulation, subsequently lowering the chances of underestimation of disease severity, especially for localized diseases. Furthermore, MNs are capable of providing (near) real-time diagnosis, and it is easily administrated with simple procedures. Thus, MNs are potential candidates for Point-of-care (PoC) testing which could be conducted bedside. Hollow MNs and hydrogel MNs could be used to diagnose and monitor several diseases including Cataracts, Diabetes, Cancer, and Alzheimer's disease. For instance, hollow glass MNs and hydrogel MNs could extract skin interstitial fluid for the detection of glucose levels.
=== Resolution phase === In the Resolution phase, pathogens and damaged tissue are removed by macrophages (white blood cells). Red blood cells are also removed from the damaged tissue by macrophages. Failure to remove all of the damaged cells and pathogens may retrigger inflammation. The two subsets of macrophage M1 & M2 plays a crucial role in this phase, M1 macrophage being a pro inflammatory while as M2 is a regenerative and the plasticity between the two subsets determine the tissue inflammation or repair.
It was scheduled for release in August 2000 but canceled by the publisher Sierra Entertainment by this time. As Kudirka reported to id Software that he had been taken off a project, the studio referred him to the director Steven Spielberg. His company DreamWorks SKG had experimented with developing a personal computer follow-up to Medal of Honor but decided to work with an external partner instead. In May 2000, 2015 began work on what became Medal of Honor: Allied Assault. According to Kudirka, shortly before the release of Allied Assault, the studio director of development Vince Zampella began secretly meeting with Electronic Arts to establish a separate studio and take over most staff. Out of 27 employees, 20 had resigned by the end of the month. Zampella and Jason West founded Infinity Ward, which ultimately hired 22 former 2015 staffers. Rieke, who also left, said the development team had bonded but sought to work under a different management. In response to the departures, Kudirka filed a lawsuit against Zampella, which was settled when Activision bought a 30% stake in Infinity Ward. Allied Assault was a critical and commercial success, selling 1.5 million copies within a year. In January 2003, Vivendi Universal Games announced Men of Valor as 2015's next game for Windows and the Xbox. By March, 2015 had grown to 39 people, with John Whitmore as the new director of development. Men of Valor, released in 2004, was not as commercially successful as Allied Assault and subsequent attempts to pitch games to publishers failed.
Sources: en.wikipedia.org
(2026) reconstruct the diet of Miocene rodents and South American native ungulates from the La Venta site (Colombia) on the basis of stable isotope analyses of tooth enamel, reporting evidence of C3-dominated diets of the studied mammals, but also evidence of ecological differentiation. Casanovas-Vilar et al. (2026) interpret the small mammal assemblage from the Vallès-Penedès Basin (Spain) as consistent with a climate during the Miocene that was transitional between humid subtropical and Mediterranean types, finding no evidence of significant climate changes at the times of major faunal turnovers. Martín-Perea et al. (2026) study the taphonomy of late Miocene mammalian assemblages from the Daidian and Dongmen sites (China), and interpret the studied assemblages as resulting from gradual accumulation through attritional mortality. Evidence from fossil data from low latitudes in Mexico, indicating that the dispersal of North American mammals into South America during the Great American Interchange was preceded and primed by their accumulation in Mexico beginning 10 million years ago, is presented by Tseng et al. (2026).
The Covenant of Religious Socialists of Germany (Bund der Religiösen Sozialistinnen und Sozialisten Deutschlands, BRSD) is an organization of German Protestants who are working for a socialist society. It was founded in 1926 and was banned during the Nazi era (1933–1945), but reconstituted itself again, after the war.
== Economy == Fishing is the primary occupation. The islands have strategic and economic value, in terms of fisheries and also mineral deposits of pyrite, sulfur, and various polymetallic ores. There are hopes that oil exploration will provide an economic boost to the islands. In 2014, construction workers built a pier and a breakwater in Kitovy Bay, central Iturup, where barges are a major means of transport, sailing between the cove and ships anchored offshore. A new road has been carved through the woods near Kurilsk, the island's biggest village, going to the site of Iturup Airport (on Kunashir, the neighboring island south of Iturup, there exists Yuzhno-Kurilsk Mendeleyevo Airport). Gidrostroy, the Kurils' biggest business group with interests in fishing, construction and real estate, built its second fish processing factory on Iturup island in 2006, introducing a state-of-the-art conveyor system. To deal with a rise in the demand of electricity, the local government is also upgrading a state-run geothermal power plant at Mount Baransky, an active volcano, where steam and hot water can be found. In 2022, a special economic zone was established on the Kuril islands with special tax regimes, exemption from corporate income tax, VAT with reduced customs duties for 20 years. It is an important part of Russian government's plan to develop the Russian far east.
== Development and release == Garry's Mod was created by the programmer Garry Newman. He started developing games under the studio name Facepunch Studios after dropping out of college, at the time out of his parents' house. He did this as a hobby, simultaneous to his occupation as a PHP programmer for a dating website. He was later fired when he launched his own dating website. While developing his first game, Facewound, Garry's Mod became a side-project of his as a mod for the Source game engine and, principally, the game Half-Life 2. Newman soon found more enjoyment in developing Garry's Mod than in maintaining Facewound, so development on Facewound was mostly halted (and put on indefinite hiatus in 2004) for him to focus on Garry's Mod. He stated that, at the time, his skills in computer programming were not advanced enough to create a full Source-based game and he resorted to the mod format. The first iteration of the mod, version 1, was released on 24 December 2004. Initial feedback was polarised, with some players criticising the mod for its similarity to an existing mod, JBMod. However, the increasing positive reception led Newman to continue development. Newman did not recognise that the game was gaining in popularity until he set up an online forum for it. Through 2004 and 2005, Newman released several updated versions of Garry's Mod, adding new features and culminating in version 9.0.4 on 27 November 2005. Newman began work on remaking the mod into a standalone game with assistance from community members.
== Non-industrial uses == The direct use of ethylene oxide accounts for only 0.05% (2004 data) of its global production. Ethylene oxide is used as a sterilizing agent, disinfecting agent and fumigant as a mixture with carbon dioxide (8.5–80% of ethylene oxide), nitrogen, or dichlorodifluoromethane (12% ethylene oxide). It is applied for gas-phase sterilization of medical equipment and instruments, packaging materials, clothing, and surgical and scientific equipment; for processing of storage facilities (tobacco, packages of grain, sacks of rice, etc.), clothing, furs, and valuable documents.
Sources: en.wikipedia.org
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.
Rodents account for the large majority of published experiments. Human data are sparse and mostly observational, so cross-species extrapolation remains uncertain.
It is not an approved therapeutic in most jurisdictions. Regulatory status varies by country, and several places restrict it as a research chemical.
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.